Gilead’s First-In-Class Drug For Aggressive Breast Cancer On Track For EU Approval

Conditional Approval In Store For Janssen’s Non-Small Cell Lung Cancer Treatment

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".